Rate control drugs differ in the prevention of progression of atrial fibrillation

T. Koldenhof*, P.E.P.J. Wijtvliet, N.A.H.A. Pluymaekers, M. Rienstra, R.J. Folkeringa, P. Bronzwaer, A. Elvan, J. Elders, R. Tukkie, J.G.L.M. Luermans, S.M.J. van Kuijk, J.G.P. Tijssen, I.C. van Gelder, H.J.G.M. Crijns, R.G. Tieleman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)384-389
Number of pages6
JournalEP Europace
Volume24
Issue number3
Early online date20 Aug 2021
DOIs
Publication statusPublished - 2 Mar 2022

Keywords

  • Atrial fibrillation
  • Atrial fibrillation progression
  • Rate control
  • Rhythm control
  • RACE 4 study
  • VERAPAMIL
  • TACHYCARDIA
  • ARRHYTHMOGENESIS
  • CARDIOVERSION
  • DIGOXIN
  • RISK

Cite this